NeuBase Therapeutics, Inc.

NasdaqCM:NBSE 株式レポート

時価総額:US$1.4m

NeuBase Therapeutics マネジメント

マネジメント 基準チェック /14

現在、CEO に関する十分な情報がありません。

主要情報

Todd Branning

最高経営責任者

n/a

報酬総額

CEO給与比率n/a
CEO在任期間2.3yrs
CEOの所有権0.04%
経営陣の平均在職期間データなし
取締役会の平均在任期間3.5yrs

経営陣の近況

Recent updates

Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

Aug 26
Can NeuBase Therapeutics (NASDAQ:NBSE) Afford To Invest In Growth?

NeuBase Therapeutics GAAP EPS of -$0.26 beats by $0.04

Aug 11

NeuBase Therapeutics promotes Dr. William Mann to President and COO

Jun 29

We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

May 12
We Think NeuBase Therapeutics (NASDAQ:NBSE) Needs To Drive Business Growth Carefully

Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Jan 24
Is NeuBase Therapeutics (NASDAQ:NBSE) In A Good Position To Deliver On Growth Plans?

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Oct 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Jun 02
Here's Why We're Not Too Worried About NeuBase Therapeutics' (NASDAQ:NBSE) Cash Burn Situation

Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

Feb 23
Have Insiders Been Buying NeuBase Therapeutics, Inc. (NASDAQ:NBSE) Shares This Year?

We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

Jan 19
We Think NeuBase Therapeutics (NASDAQ:NBSE) Can Afford To Drive Business Growth

NeuBase Therapeutics EPS in-line

Dec 23

NeuBase Therapeutics reports encouraging data for PATrOL-enabled anti-gene in a type of muscular dystrophy

Dec 16

Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

Dec 15
Do Insiders Own Lots Of Shares In NeuBase Therapeutics, Inc. (NASDAQ:NBSE)?

CEO報酬分析

NeuBase Therapeutics の収益と比較して、Todd Branning の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2023n/an/a

-US$25m

Dec 31 2022n/an/a

-US$30m

Sep 30 2022US$922kUS$311k

-US$34m

報酬と市場: Toddの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。

報酬と収益: Toddの報酬と会社の業績を比較するにはデータが不十分です。


CEO(最高経営責任者

Todd Branning (53 yo)

2.3yrs

在職期間

US$922,445

報酬

Mr. Todd P. Branning serves as an Interim Chief Executive Officer since January 16, 2024 and Chief Financial Officer of NeuBase Therapeutics, Inc. since January 2022 and serves as its Secretary. He joined...


取締役

名称ポジション在職期間報酬所有権
Dietrich Stephan
Founder4.8yrsUS$1.15m6.14%
$ 87.1k
Dov Goldstein
Independent Chairperson4.8yrsUS$74.42k0.040%
$ 567.0
Eric Richman
Independent Director4.8yrsUS$68.38k0.060%
$ 849.3
George Church
Chairperson of Gene Editing Advisory Board & Member of Scientific Advisory Boardless than a yearデータなしデータなし
Steven Dowdy
Member of Gene Editing & Scientific Advisory Board4.6yrsデータなしデータなし
James Coull
Member of Gene Editing Advisory Boardless than a yearデータなしデータなし
Randy Davis
Member of Scientific Advisory Board3.5yrsデータなしデータなし
Danith Ly
Member of Advisory Boardno dataデータなしデータなし
Robert Friedlander
Chair of Scientific Advisory Boardno dataデータなしデータなし
Peter Nielsen
Member of Gene Editing & Scientific Advisory Board3.6yrsデータなしデータなし
Eriks Rozners
Member of Gene Editing & Scientific Advisory Board3.5yrsデータなしデータなし
Gerald Mcdougall
Independent Director3yrsUS$59.79k0%
$ 0

3.5yrs

平均在職期間

56yo

平均年齢

経験豊富なボード: NBSEの 取締役会経験豊富 であると考えられます ( 3.5年の平均在任期間)。